Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing, and pathological activation. The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised development of treatment programs for the treatment and management of symptoms of the anti-synthetic syndrome of the HMGCR is required, usually including drug therapy, rehabilitation, regular follow-up, and multidimensional management.
In recent years, with the development of therapeutic-focused, immune-regulatory therapies and precision medicine, many previously difficult-to-treat autoimmune and rheumatoid immune disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of HMGCR with anti-synthetase syndrome.
The platform serves the China International Medical Service System, which combines a team of authoritative experts at home and abroad in the field of autoimmunity and rheumatic immunity, to provide the following services to patients: 1. Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangement with authoritative experts for face-to-face diagnosis, development of personalized treatment plans; 3.
Full-service: One-stop services: medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.